Medical Thawing System Market by Sample Type (Blood, Embryo, Ovum, and Semen) and End User (Blood Banks, Hospitals, Tissue Banks, Pharmaceutical & Biotech Companies, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global medical thawing system market was valued at $165.82 million in 2019 and is expected to reach $279.17 million by 2027 with a CAGR of 11.6% during the forecast period. Thawing system is the process developed to defrost biological samples in cell biology research. Biology research is used in drug discovery, bio-banking, assisted reproduction, cellular therapy, and regenerative medicine. This system is required to transport and store pharmaceutical products & services in the biopharmaceutical industry. Automated thawing instruments are designed to rapidly thaw live biological contents of a cryogenic vial with high reproducibility and minimal risk of contamination. Increase in incidences of chronic disease lead to demand for blood and plasma products and technological advancements to simplify the process of thawing, which propels the market growth. In addition, rise in awareness and government initiatives toward plasma donation, rise in launches and agreement of medical thawing systems, increase in number of embryo donors, and rise in awareness of third-party reproduction further drive the market growth. However, high cost of automation hinders the market growth. Moreover, direct need for novel medicinal inventions to push adoption of thawing systems is expected to provide lucrative market growth during the forecast period.
The medical thawing system market is divided on the basis of sample type, end user, and region. By sample, the market is segmented into blood, embryo, ovum, and semen. On the basis of end user, it is segmented into blood banks, hospitals, tissue banks, pharmaceutical and biotech companies, and others. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Competitive rivalry in the global medical thawing system market was observed at high level as major market participants are focused on the adoption of growth strategies such as product launches, agreement and acquisitions to gain substantial share in the competitive market. Prominent companies operating in the global medical thawing system market include Barkey GmbH & Co. KG, Boekel Scientific, BioLife Solutions Inc, Cardinal Health, Inc., General Electric Company, Helmer Scientific, Sartorius AG, Sarstedt AG & Co. KG, Terumo Corporation, and Thermo Fisher Scientific Inc.
KEY BENEFITS FOR STAKEHOLDERS • The study provides an in-depth analysis of the global medical thawing system market with current trends and future estimations from 2019 to 2027 to elucidate the imminent investment pockets. • Comprehensive analysis of factors that drive and restrict the market growth is provided. • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided. • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Key Market Segments
By Sample Type • Blood • Embryo • Ovum • Semen
By End User • Blood Banks • Hospitals • Tissue Banks • Pharmaceutical and Biotech Companies • Others
By Region o North America U.S. Canada Mexico o Europe UK Germany France Italy Spain Rest of Europe o Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific o LAMEA • Brazil • Saudi Arabia • South Africa • Rest of LAMEA
List of key players profiled in the report • Barkey GmbH & Co. KG • Boekel Scientific • BioLife Solutions Inc. • Cardinal Health, Inc. • General Electric Company • Helmer Scientific • Sartorius AG • Sarstedt AG & Co. KG • Terumo Corporation • Thermo Fisher Scientific Inc.
List of the other key players (not included in the report) includesARCOX TMC GROUP, LABCOLD, Abbott, Medtronic, Brainlab AG, Varian Medical Systems, Inc., Olympus Corporation and KARL STORZ SE & Co. KG.
Our reports have been used by over 10K customers, including:
Global Coronavirus Partnering 2014 to 2021 provides the full collection of Coronavirus disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Coronavirus partnering deals Financial deal terms for headline, upfront and royalty by stage of development Coronavirus...
703 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Mar 2021
Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to the analysis,...
The Global Microbiome Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Microbiome partnering deals Disclosed headlines, upfronts, milestones and royalties by...
The Asia Pacific microplate readers market is expected to reach US$ 152.15 million by 2027 from US$ 110.87 million in 2019; it is estimated to grow at a CAGR of 4.1% from 2020 to 2027. The growth of the market is attributed to the factors such as technological advancements in microplate readers and consistent research in drug discovery activities....
The North America yeast extract market is expected to reach US$ 561.2 million in 2027 from US$ 389.6 million in 2019. The market is estimated to grow at a CAGR of 4.7% during 2020–2027. The growth the North America yeast extract market is attributed to the key driving factors such as the rising demand for natural ingredients in the...
555 pages •
By Global Industry Analysts
• Apr 2021
- Most R&D budgets which are so vital for innovation are largely dependent upon financial support from governments. Healthy financial performance of companies also determines the extent of willingness to reinvest earnings into R&D and new product development. The COVID-19 induced recession has now cast serious...
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of distribution agreements from...
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2021 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The report provides a detailed understanding and analysis of how and why companies enter business, product,...
131 pages •
By Global Industry Analysts
• Apr 2021
- Global Lysosomal Storage Diseases Market to Reach $10.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Lysosomal Storage Diseases estimated at US$7 Billion in the year 2020, is projected to reach a revised size of US$10.3 Billion by 2027, growing at a CAGR of 5.6% over the analysis period...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.